U. Vanleeuw

发表

Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis

R. Paridaens, M. Christiaens, J. Decock, 2008, Breast Cancer Research.

Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma

R. Sciot, P. Schöffski, A. Wozniak, 2022, Biomedicines.

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models

R. Sciot, M. Debiec‐Rychter, P. Schöffski, 2014, Translational oncology.

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models

R. Sciot, G. Floris, M. Debiec‐Rychter, 2015, Translational oncology.

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors

R. Sciot, G. Floris, M. Debiec‐Rychter, 2014, Clinical Sarcoma Research.

Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis

V. Van Belle, S. Van Huffel, R. Paridaens, 2008, BMC Cancer.

Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy

J. Fletcher, R. Sciot, G. Floris, 2014, Clinical Cancer Research.

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing

D. Lambrechts, R. Sciot, M. Debiec‐Rychter, 2019, Molecular Cancer Therapeutics.

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

A. Gardino, R. Sciot, M. Debiec‐Rychter, 2018, Clinical Cancer Research.

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations

R. Sciot, M. Debiec‐Rychter, P. Schöffski, 2016, Molecular Cancer Therapeutics.

The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

R. Sciot, G. Floris, M. Debiec‐Rychter, 2011, Molecular Cancer Therapeutics.

Preclinical Development The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation , Tumor Shrinkage , and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

R. Sciot, G. Floris, M. Debiec‐Rychter, 2011 .

The heat shock protein 90 inhibitor IPI-504 induces KIT degradation , tumor shrinkage and cell proliferation arrest in xenografts models of gastrointestinal stromal tumors

R. Sciot, G. Floris, M. Debiec‐Rychter, 2011 .

Abstract 1460: Establishment and characterization of a panel of patient-derived soft tissue sarcoma (STS) xenograft models for in vivo testing of novel therapeutic approaches

R. Sciot, M. Debiec‐Rychter, P. Schöffski, 2015 .

Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research

R. Sciot, C. Britschgi, P. Schöffski, 2021, Sarcoma.

In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models

R. Sciot, M. Debiec‐Rychter, P. Pokreisz, 2017, Molecular Cancer Therapeutics.

The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

R. Sciot, G. Floris, G. Faa, 2011, Molecular Cancer Therapeutics.

Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST).

R. Sciot, P. Schöffski, A. Wozniak, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.